21205-Breast Cancer-NA-22

Breast Cancer

EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

  • Details

ClinicalTrials.gov ID: NCT04899349
Diagnosis Type: NA
USOR Number:

  • Address

1700 S Potomac Street
Aurora, CO 80012
P: (303) 418-7600

Search by practice name, trial titles, indicators and specific disease types.